SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Petco Health & Wellness Co., Inc. – ‘8-K’ for 3/12/24 – ‘EX-99.1’

On:  Wednesday, 3/13/24, at 7:17am ET   ·   For:  3/12/24   ·   Accession #:  1193125-24-66384   ·   File #:  1-39878

Previous ‘8-K’:  ‘8-K’ on / for 2/26/24   ·   Next:  ‘8-K’ on 4/9/24 for 4/4/24   ·   Latest:  ‘8-K’ on 5/14/24 for 5/13/24   ·   1 Reference:  By:  Petco Health & Wellness Co., Inc. – ‘10-K’ on 4/3/24 for 2/3/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/24  Petco Health & Wellness Co., Inc. 8-K:2,5,7,9 3/12/24   14:633K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     34K 
 2: EX-10.1     Material Contract                                   HTML     15K 
 3: EX-10.2     Material Contract                                   HTML     83K 
 4: EX-99.1     Miscellaneous Exhibit                               HTML    239K 
 5: EX-99.2     Miscellaneous Exhibit                               HTML     13K 
 9: R1          Document and Entity Information                     HTML     46K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
14: XML         XBRL Instance -- d812696d8k_htm                      XML     15K 
10: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 7: EX-101.LAB  XBRL Labels -- woof-20240312_lab                     XML     54K 
 8: EX-101.PRE  XBRL Presentations -- woof-20240312_pre              XML     34K 
 6: EX-101.SCH  XBRL Schema -- woof-20240312                         XSD     12K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
13: ZIP         XBRL Zipped Folder -- 0001193125-24-066384-xbrl      Zip     71K 


‘EX-99.1’   —   Miscellaneous Exhibit


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-99.1  

Exhibit 99.1

 

LOGO

 

Contacts:

 

Investor Relations

Cathy Yao

cathy.yao@petco.com

     

Media Relations

 

Benjamin Thiele-Long

 

benjamin.thiele-long@petco.com

 

FOR IMMEDIATE RELEASE: March 13, 2024

Petco Health + Wellness Company, Inc. Reports Fourth Quarter and Full Year 2023 Earnings

Q4 2023 Highlights

 

 

Net revenue of $1.7 billion increased 6.1 percent year over year including the 14th week

 

 

Comparable sales declined 0.9 percent year over year and increased 4.4 percent on a two-year basis

 

 

GAAP net loss of $22.6 million, or $(0.08) per share, compared to GAAP net income of $32.7 million, or $0.12 per share in the prior year

 

 

Adjusted Net Income1 of $6.1 million, or $0.02 per share, compared to $52.8 million, or $0.20 per share in the prior year

 

 

Adjusted EBITDA1 of $105.3 million compared to $157.9 million in the prior year

 

 

Operating Cash Flow of $47.0 million compared to $136.5 million in the prior year

 

 

Free Cash Flow 1 of $(2.0) million compared to $70.6 million in the prior year

Full Year 2023 Highlights

 

 

Net revenue of $6.3 billion increased 3.6 percent year over year including the 53rd week

 

 

Comparable sales increased 1.8 percent year over year and increased 6.3 percent on a two-year basis

 

 

GAAP net loss of $1.3 billion, or $(4.78) per share, which includes goodwill impairment of $1.2B, compared to GAAP net income of $90.8 million, or $0.34 per share in the prior year

 

 

Adjusted Net Income1 of $22.8 million, or $0.09 per share, compared to $162.6 million, or $0.61 per share in the prior year

 

 

Adjusted EBITDA1 of $401.1 million compared to $530.8 million in the prior year

 

 

Operating Cash Flow of $215.7 million compared to $346.0 million in the prior year

 

 

Free Cash Flow 1 of $(9.9) million compared to $68.0 million in the prior year

San Diego, March 13, 2024 – Petco Health and Wellness Company, Inc. (Nasdaq: WOOF), a complete partner in pet health and wellness, today announced its fourth quarter and full year 2023 financial results. 

In the fourth quarter of 2023, Petco delivered net revenue of $1.7 billion, up 6.1 percent versus prior year, inclusive of a 14th week. On an as-reported basis, the company’s consumables business was up 8.8 percent versus prior year, and services and other business was up 17.4 percent versus prior year. Growth in the company’s consumables and services and other business was partially offset by the company’s supplies and companion animal business, down 1.4 percent versus prior year. GAAP net loss in the fourth

 

1


quarter of 2023 was $22.6 million or $(0.08) per share, compared to GAAP net income of $32.7 million or $0.12 per share in the prior year. Adjusted Net Income1 was $6.1 million or $0.02 per share, compared to $52.8 million or $0.20 per share in the prior year. Adjusted EBITDA1 was $105.3 million compared to $157.9 million in the prior year.

For the full year 2023, Petco delivered net revenue of $6.3 billion, up 3.6 percent versus prior year, inclusive of a 53rd week. On an as-reported basis, the company’s consumables business was up 7.1 percent versus prior year, and services and other business was up 21.9 percent versus prior year. Growth in the company’s consumables and services and other business was partially offset by its supplies and companion animal business, down 6.8 percent versus prior year. GAAP net loss of $1.3 billion or $(4.78) per share was inclusive of a goodwill impairment of $1.2B, compared to GAAP net income of $90.8 million or $0.34 per share in the prior year. Adjusted Net Income1 was $22.8 million or $0.09 per share, compared to $162.6 million or $0.61 per share in the prior year. Adjusted EBITDA1 was $401.1 million compared to $530.8 million in the prior year.

 

(1)

Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings Per Share (“Adjusted EPS”), and Free Cash Flow are non-GAAP financial measures. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.

Given the change in leadership, the company is not providing full year revenue, Adjusted EBITDA and Adjusted EPS guidance at this time. Instead, the company is providing earnings guidance for fiscal Q1. The company continues to provide interest, share count, and capital expenditure expectations for the full year.

Fiscal Q1 2024 Outlook

For Fiscal Q1 2024, the company expects:

 

Metric*

   FQ1 2024
Guidance
 

Net Revenue

   ~ $ 1.5 billion  

Adjusted EBITDA

   ~ $ 70 million  

Adjusted EPS

   ~ $ (0.06

Fiscal 2024 Outlook

For Fiscal 2024 (a 52-week year), the company expects:

 

Metric*

   2024
Guidance, YoY
 

Net interest expense

   ~$ 145 million  

Capital Expenditures

   ~$ 140 million  

 

2


*

Assumptions in the guidance include that economic conditions, currency rates and the tax and regulatory landscape remain generally consistent. For fiscal 2024, our guidance anticipates a 26 percent tax rate, and 272 million weighted average diluted share count. Adjusted EBITDA and Adjusted EPS are non-GAAP financial measures and have not been reconciled to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management’s control and which could be significant. Because such items cannot be reasonably predicted with the level of precision required, we are unable to provide outlook for the comparable GAAP measures. Forward-looking estimates of Adjusted EBITDA and Adjusted EPS are made in a manner consistent with the relevant definitions and assumptions noted herein and in our filings with the Securities and Exchange Commission.

Earnings Conference Call Webcast Information:

Management will host an earnings conference call on March 13, 2024 at 8:00 AM Eastern Time to discuss the company’s financial results. The conference call will be accessible through a live webcast. Interested investors and other individuals can access the webcast, earnings release, earnings presentation, infographic, and earnings supplement via the company’s investor relations page at ir.petco.com. A replay of the webcast will be archived on the company’s investor relations page through March 27, 2024 until approximately 5:00 PM Eastern Time.

About Petco, The Health + Wellness Co.:

Founded in 1965, Petco is a category-defining health and wellness company focused on improving the lives of pets, pet parents and our own Petco partners. We’ve consistently set new standards in pet care while delivering comprehensive pet wellness products, services and solutions, and creating communities that deepen the pet-pet parent bond. We operate more than 1,500 pet care centers across the U.S., Mexico and Puerto Rico, which offer merchandise, companion animals, grooming, training and a growing network of on-site veterinary hospitals and mobile veterinary clinics. Our complete pet health and wellness ecosystem is accessible through our pet care centers and digitally at petco.com and on the Petco app. In tandem with Petco Love, a life-changing organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we’ve helped find homes for nearly 7 million animals.

Forward-Looking Statements:

This earnings release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact, including, but not limited

 

3


to, statements regarding our Q1 and fiscal year 2024 guidance, operational reset of our business, our competitive positioning, profitability, cost action plans and associated cost-savings. Such forward-looking statements can generally be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “intends,” “will,” “shall,” “should,” “anticipates,” “opportunity,” “illustrative,” or the negative thereof or other variations thereon or comparable terminology. Although Petco believes that the expectations and assumptions reflected in these statements are reasonable, there can be no assurance that these expectations will prove to be correct or that any forward-looking results will occur or be realized. Nothing contained in this earnings release is, or should be relied upon as, a promise or representation or warranty as to any future matter, including any matter in respect of the operations or business or financial condition of Petco. All forward-looking statements are based on current expectations and assumptions about future events that may or may not be correct or necessarily take place and that are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Petco. Forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results or events to differ materially from the potential results or events discussed in the forward-looking statements, including, without limitation, those identified in this earnings release as well as the following: (i) increased competition (including from multi-channel retailers and e-Commerce providers); (ii) reduced consumer demand for our products and/or services; (iii) our reliance on key vendors; (iv) our ability to attract and retain qualified employees; (v) risks arising from statutory, regulatory and/or legal developments; (vi) macroeconomic pressures in the markets in which we operate, including inflation and prevailing interest rates; (vii) failure to effectively manage our costs; (viii) our reliance on our information technology systems; (ix) our ability to prevent or effectively respond to a data privacy or security breach; (x) our ability to effectively manage or integrate strategic ventures, alliances or acquisitions and realize the anticipated benefits of such transactions; (xi) economic or regulatory developments that might affect our ability to provide attractive promotional financing; (xii) business interruptions and other supply chain issues; (xiii) catastrophic events, political tensions, conflicts and wars (such as the ongoing conflict in Ukraine), health crises, and pandemics; (xiv) our ability to maintain positive brand perception and recognition; (xv) product safety and quality concerns; (xvi) changes to labor or employment laws or regulations; (xvii) our ability to effectively manage our real estate portfolio; (xviii) constraints in the capital markets or our vendor credit terms; (xix) changes in our credit ratings; (xx) impairments of the carrying value of our goodwill and other intangible assets; (xxi) our ability to successfully implement our operational adjustments, achieve the expected benefits of our cost action plans and drive improved profitability; and (xxii) the other risks, uncertainties and other factors identified under “Risk Factors” and elsewhere in Petco’s Securities and Exchange Commission filings. The occurrence of any such factors could significantly alter the results set forth in these statements.

Petco cautions that the foregoing list of risks, uncertainties and other factors is not complete, and forward-looking statements speak only as of the date they are made. Petco undertakes no duty to update publicly any such forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by applicable law, regulation or other competent legal authority.

 

4


PETCO HEALTH AND WELLNESS COMPANY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited and subject to reclassification)

 

     14 Weeks     13 Weeks           53 Weeks     52 Weeks        
     Ended     Ended    

 

    Ended     Ended    

 

 
     February 3,     January 28,     Percent     February 3,     January 28,     Percent  
     2024     2023     Change     2024     2023     Change  

Net sales:

            

Products

   $ 1,420,713     $ 1,361,856       4   $ 5,273,710     $ 5,230,515       1

Services and other

     253,763       216,103       17     981,574       805,452       0  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total net sales

     1,674,476       1,577,959       6     6,255,284       6,035,967       4

Cost of sales:

            

Products

     903,156       805,938       12     3,269,628       3,035,249       8

Services and other

     164,972       144,742       14     631,821       573,611       10
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of sales

     1,068,128       950,680       12     3,901,449       3,608,860       8
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     606,348       627,279       (3 %)      2,353,835       2,427,107       (3 %) 

Selling, general and administrative expenses

     606,182       549,719       10     2,311,625       2,201,548       5

Goodwill and indefinite-lived intangible impairment

     —        —        N/M       1,222,524       —        N/M  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating income (loss)

     166       77,560       (100 %)      (1,180,314     225,559       N/M  

Interest income

     (326     (745     (56 %)      (3,405     (1,032     230

Interest expense

     39,658       32,882       21     150,909       101,643       48

Loss on extinguishment and modification of debt

     —        —        N/M       920       —        N/M  

Other non-operating loss (income)

     —        3,298       (100 %)      (4,727     12,667       N/M  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) income before income taxes and income from equity method investees

     (39,166     42,125       N/M       (1,324,011     112,281       N/M  

Income tax (benefit) expense

     (10,435     14,548       N/M       (27,613     35,347       N/M  

Income from equity method investees

     (6,156     (5,155     19     (16,188     (12,976     25
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income

     (22,575     32,732       N/M       (1,280,210     89,910       N/M  

Net loss attributable to noncontrolling interest

     —        —        N/M       —        (891     (100 %) 
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss) income attributable to Class A and B-1 common stockholders

   $ (22,575   $ 32,732       N/M     $ (1,280,210   $ 90,801       N/M  

Net (loss) income per Class A and B-1 common share:

            

Basic

   $ (0.08   $ 0.12       N/M     $ (4.78   $ 0.34       N/M  

Diluted

   $ (0.08   $ 0.12       N/M     $ (4.78   $ 0.34       N/M  

Weighted average shares used in computing net (loss) income per Class A and B-1 common share:

            

Basic

     268,615       265,918       1     267,549       265,522       1

Diluted

     268,615       266,297       1     267,549       265,951       1

 

5


PETCO HEALTH AND WELLNESS COMPANY, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited and subject to reclassification)

 

     February 3,     January 28,  
     2024     2023  

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 125,428     $ 201,901  

Receivables, less allowance for credit losses1

     44,369       49,580  

Merchandise inventories, net

     684,502       652,430  

Prepaid expenses

     58,615       51,274  

Other current assets

     38,830       60,809  
  

 

 

   

 

 

 

Total current assets

     951,744       1,015,994  
  

 

 

   

 

 

 

Fixed assets, net

     816,367       803,327  

Operating lease right-of-use assets

     1,384,050       1,397,761  

Goodwill

     980,297       2,193,941  

Trade name

     1,025,000       1,025,000  

Other long-term assets

     205,694       176,806  
  

 

 

   

 

 

 

Total assets

   $ 5,363,152     $ 6,612,829  
  

 

 

   

 

 

 

LIABILITIES AND EQUITY

    

Current liabilities:

    

Accounts payable and book overdrafts

   $ 485,131     $ 381,213  

Accrued salaries and employee benefits

     101,265       89,929  

Accrued expenses and other liabilities

     200,278       217,556  

Current portion of operating lease liabilities

     310,507       309,766  

Current portion of long-term debt and other lease liabilities

     15,962       22,794  
  

 

 

   

 

 

 

Total current liabilities

     1,113,143       1,021,258  
  

 

 

   

 

 

 

Senior secured credit facilities, net, excluding current portion

     1,576,223       1,628,331  

Operating lease liabilities, excluding current portion

     1,116,615       1,148,155  

Deferred taxes, net

     251,629       303,121  

Other long-term liabilities

     121,113       130,487  
  

 

 

   

 

 

 

Total liabilities

     4,178,723       4,231,352  
  

 

 

   

 

 

 

Commitments and contingencies

    

Stockholders’ equity:

    

Class A common stock2

     231       228  

Class B-1 common stock3

     38       38  

Class B-2 common stock4

     —        —   

Preferred stock5

     —        —   

Additional paid-in-capital

     2,229,582       2,152,342  

(Accumulated deficit) retained earnings

     (1,047,243     232,967  

Accumulated other comprehensive income (loss)

     1,821       (4,098
  

 

 

   

 

 

 

Total stockholders’ equity

     1,184,429       2,381,477  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 5,363,152     $ 6,612,829  
  

 

 

   

 

 

 

 

(1)

Allowances for credit losses are $1,806 and $952, respectively

(2)

Class A common stock, $0.001 par value: Authorized - 1.0 billion shares; Issued and outstanding - 231.2 million and 228.3 million shares, respectively

(3)

Class B-1 common stock, $0.001 par value: Authorized - 75.0 million shares; Issued and outstanding - 37.8 million shares

(4)

Class B-2 common stock, $0.000001 par value: Authorized - 75.0 million shares; Issued and outstanding - 37.8 million shares

(5)

Preferred stock, $0.001 par value: Authorized - 25.0 million shares; Issued and outstanding - none

 

6


PETCO HEALTH AND WELLNESS COMPANY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited and subject to reclassification)

 

     53 Weeks     52 Weeks  
     Ended     Ended  
     February 3,     January 28,  
     2024     2023  

Cash flows from operating activities:

    

Net (loss) income

   $ (1,280,210   $ 89,910  

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

    

Depreciation and amortization

     200,782       193,828  

Amortization of debt discounts and issuance costs

     4,972       4,940  

Provision for deferred taxes

     (53,549     (893

Equity-based compensation expense

     81,859       60,784  

Impairments, write-offs and losses on sale of fixed and other assets

     2,833       1,992  

Loss on extinguishment and modification of debt

     920       —   

Income from equity method investees

     (16,188     (12,976

Amounts reclassified out of accumulated other comprehensive income

     (488     168  

Goodwill impairment

     1,222,524       —   

Non-cash operating lease costs

     429,056       422,792  

Other non-operating (income) loss

     (4,727     12,667  

Changes in assets and liabilities:

    

Receivables

     5,211       6,038  

Merchandise inventories

     (32,072     22,681  

Prepaid expenses and other assets

     (8,009     (5,933

Accounts payable and book overdrafts

     103,919       (22,763

Accrued salaries and employee benefits

     11,347       (51,427

Accrued expenses and other liabilities

     (8,495     13,616  

Operating lease liabilities

     (446,981     (386,259

Other long-term liabilities

     3,015       (3,162
  

 

 

   

 

 

 

Net cash provided by operating activities

     215,719       346,003  
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Cash paid for fixed assets

     (225,598     (278,020

Cash paid for acquisitions, net of cash acquired

     (6,725     (9,640

Cash paid for interest in veterinary joint venture

     —        (35,000

Proceeds from investment

     24,878       —   

Proceeds from sale of assets

     —        2,336  
  

 

 

   

 

 

 

Net cash used in investing activities

     (207,445     (320,324
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Borrowings under long-term debt agreements

     273,000       123,000  

Repayments of long-term debt

     (348,000     (140,000

Payments for finance lease liabilities

     (5,925     (5,083

Proceeds from employee stock purchase plan and stock option exercises

     4,223       3,796  

Tax withholdings on stock-based awards

     (8,650     (15,555
  

 

 

   

 

 

 

Net cash used in financing activities

     (85,352     (33,842
  

 

 

   

 

 

 

Net decrease in cash, cash equivalents and restricted cash

     (77,078     (8,163

Cash, cash equivalents and restricted cash at beginning of period

     213,727       221,890  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash at end of period

   $ 136,649     $ 213,727  
  

 

 

   

 

 

 

 

7


NON-GAAP FINANCIAL MEASURES

The following information provides definitions and reconciliations of the non-GAAP financial measures presented in this earnings release to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles (GAAP). The company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measures in this earnings release may differ from similarly titled measures used by other companies.

The tables below reflect the calculation of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS, as applicable, for the fourteen and fifty-three weeks ended February 3, 2024 compared to the thirteen and fifty-two weeks ended January 28, 2023, respectively.

 

8


Adjusted EBITDA and Trailing Twelve Month Adjusted EBITDA

Adjusted EBITDA, including Trailing Twelve Month Adjusted EBITDA, is considered a non-GAAP financial measure under the Securities and Exchange Commission’s (SEC) rules because it excludes certain amounts included in net income calculated in accordance with GAAP. Management believes that Adjusted EBITDA is a meaningful measure to share with investors because it facilitates comparison of the current period performance with that of the comparable prior period. In addition, Adjusted EBITDA affords investors a view of what management considers to be Petco’s core operating performance as well as the ability to make a more informed assessment of such operating performance as compared with that of the prior period. Please see the company’s Annual Report on Form 10-K for the fiscal year ended January 28, 2023 filed with the SEC on March 28, 2023 for additional information on Adjusted EBITDA.

 

(dollars in thousands)    14 Weeks
Ended
    13 Weeks
Ended
    53 Weeks
Ended
    52 Weeks
Ended
 
Reconciliation of Net (Loss) Income Attributable to Class A and B-1    February 3,     January 28,     February 3,     January 28,  
Common Stockholders to Adjusted EBITDA    2024     2023     2024     2023  

Net (loss) income attributable to Class A and B-1 common stockholders

   $ (22,575   $ 32,732     $ (1,280,210   $ 90,801  

Add (deduct):

        

Interest expense, net

     39,332       32,137       147,504       100,611  

Income tax (benefit) expense

     (10,435     14,548       (27,613     35,347  

Depreciation and amortization

     52,189       50,229       200,782       193,828  

Income from equity method investees

     (6,156     (5,155     (16,188     (12,976

Loss on debt extinguishment and modification

     —        —        920       —   

Goodwill impairment

     —        —        1,222,524       —   

Losses (gains) on sale of assets, impairments and write-offs

     631       (307     2,833       1,992  

Equity-based compensation expense

     17,428       19,892       81,859       60,784  

Other non-operating loss (income)

     —        3,298       (4,727     12,667  

Mexico joint venture EBITDA (1)

     11,759       9,265       38,226       29,584  

Acquisition-related integration costs (2)

     —        627       —        15,314  

Other costs (3)

     23,167       623       35,193       2,817  
  

 

 

   

 

 

   

 

 

   

 

 

 

Adjusted EBITDA

   $ 105,340     $ 157,889     $ 401,103     $ 530,769  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net sales

   $ 1,674,476     $ 1,577,959     $ 6,255,284     $ 6,035,967  

Net margin (4)

     (1.3 %)      2.1     (20.5 %)      1.5

Adjusted EBITDA Margin

     6.3     10.0     6.4     8.8

 

9


Adjusted Net Income and Adjusted EPS

Adjusted Net Income and Adjusted diluted Earnings Per Share attributable to Petco common stockholders (Adjusted EPS) are considered non-GAAP financial measures under the SEC’s rules because they exclude certain amounts included in the net income attributable to Petco common stockholders and diluted earnings per share attributable to Petco common stockholders calculated in accordance with GAAP. Management believes that Adjusted Net Income and Adjusted EPS are meaningful measures to share with investors because they facilitate comparison of the current period performance with that of the comparable prior period. In addition, Adjusted Net Income and Adjusted EPS afford investors a view of what management considers to be Petco’s core earnings performance as well as the ability to make a more informed assessment of such earnings performance with that of the prior period.

 

(in thousands, except per share amounts)    14 Weeks Ended      13 Weeks Ended  
Reconciliation of Diluted EPS to Adjusted EPS    February 3, 2024      January 28, 2023  
     Amount      Per share      Amount      Per share  

Net (loss) income attributable to common stockholders / diluted EPS

   $ (22,575    $ (0.08    $ 32,732      $ 0.12  

Add (deduct):

           

Income tax (benefit) expense

     (10,435      (0.04      14,548        0.05  

Loss on debt extinguishment and modification

     —         —         —         —   

Goodwill impairment

     —         —         —         —   

Losses (gains) on sale of assets, impairments and write-offs

     631        0.00        (307      (0.00

Equity-based compensation expense

     17,428        0.06        19,892        0.08  

Other non-operating loss

     —         —         3,298        0.02  

Acquisition-related integration costs (2)

     —         —         627        0.00  

Other costs (3)

     23,167        0.09        623        0.00  
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted pre-tax income / diluted earnings per share

   $ 8,216      $ 0.03      $ 71,413      $ 0.27  

Income tax expense at 26% normalized tax rate

     2,136        0.01        18,567        0.07  
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted Net Income / Adjusted EPS

   $ 6,080      $ 0.02      $ 52,846      $ 0.20  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(in thousands, except per share amounts)    53 Weeks Ended      52 Weeks Ended  
Reconciliation of Diluted EPS to Adjusted EPS    February 3, 2024      January 28, 2023  
     Amount      Per share      Amount      Per share  

Net (loss) income attributable to common stockholders / diluted EPS

   $ (1,280,210    $ (4.78    $ 90,801      $ 0.34  

Add (deduct):

           

Income tax (benefit) expense

     (27,613      (0.10      35,347        0.13  

Loss on debt extinguishment and modification

     920        0.00        —         —   

Goodwill impairment

     1,222,524        4.57        —         —   

Losses on sale of assets, impairments and write-offs

     2,833        0.01        1,992        0.01  

Equity-based compensation expense

     81,859        0.31        60,784        0.22  

Other non-operating (income) loss

     (4,727      (0.02      12,667        0.05  

Acquisition-related integration costs (2)

     —         —         15,314        0.06  

Other costs (3)

     35,193        0.13        2,817        0.02  
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted pre-tax income / diluted earnings per share

   $ 30,779      $ 0.12      $ 219,722      $ 0.83  

Income tax expense at 26% normalized tax rate

     8,003        0.03        57,128        0.22  
  

 

 

    

 

 

    

 

 

    

 

 

 

Adjusted Net Income / Adjusted EPS

   $ 22,776      $ 0.09      $ 162,594      $ 0.61  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

-10-


Free Cash Flow

Free Cash Flow is a non-GAAP financial measure that is calculated as net cash provided by operating activities less cash paid for fixed assets. Management believes that Free Cash Flow, which measures the ability to generate additional cash from business operations, is an important financial measure for use in evaluating the company’s financial performance.

The table below reflects the calculation of Free Cash Flow for the fourteen and fifty-three weeks ended February 3, 2024 compared to the thirteen and fifty-two weeks ended January 28, 2023, respectively.

 

(in thousands)    14 Weeks
Ended
     13 Weeks
Ended
     53 Weeks
Ended
     52 Weeks
Ended
 
     February 3,
2024
     January 28,
2023
     February 3,
2024
     January 28,
2023
 

Net cash provided by operating activities

   $ 47,023      $ 136,540      $ 215,719      $ 346,003  

Cash paid for fixed assets

     (49,066      (65,946      (225,598      (278,020
  

 

 

    

 

 

    

 

 

    

 

 

 

Free Cash Flow

   $ (2,043    $ 70,594      $ (9,879    $ 67,983  
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP Financial Measures Footnotes

 

(1)

Mexico Joint Venture EBITDA represents 50 percent of the entity’s operating results for all periods, as adjusted to reflect the results on a basis comparable to Adjusted EBITDA. In the financial statements, this joint venture is accounted for as an equity method investment and reported net of depreciation and income taxes because such a presentation would not reflect the adjustments made in the calculation of Adjusted EBITDA, we include the 50 percent interest in the company’s Mexico joint venture on an Adjusted EBITDA basis to ensure consistency. The table below presents a reconciliation of Mexico joint venture net income to Mexico joint venture EBITDA.

 

     14 Weeks
Ended
     13 Weeks
Ended
     53 Weeks
Ended
     52 Weeks
Ended
 
(in thousands)    February 3,
2024
     January 28,
2023
     February 3,
2024
     January 28,
2023
 

Net income

   $ 12,311      $ 10,309      $ 32,375      $ 24,757  

Depreciation

     7,070        5,954        26,141        19,820  

Income tax expense

     2,541        1,065        11,449        9,409  

Foreign currency (gain) loss

     557        (253      1,520        (268

Interest expense, net

     1,039        1,455        4,966        5,449  
  

 

 

    

 

 

    

 

 

    

 

 

 

EBITDA

   $ 23,518      $ 18,530      $ 76,451      $ 59,167  
  

 

 

    

 

 

    

 

 

    

 

 

 

50% of EBITDA

   $ 11,759      $ 9,265      $ 38,226      $ 29,584  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

(2)

Acquisition-related integration costs include direct costs resulting from acquiring and integrating businesses. These include third-party professional and legal fees and other integration-related costs that would not have otherwise been incurred as part of the company’s operations.

(3)

Other costs include, as incurred: restructuring costs and restructuring-related severance costs; legal reserves associated with significant, non-ordinary course legal or regulatory matters; and costs related to certain significant strategic transactions.

(4)

We define net margin as net income attributable to Class A and B-1 common stockholders divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA divided by net sales.

 

-11-


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
3/27/24
Filed on:3/13/24
For Period end:3/12/24
2/3/24
1/28/24
3/28/2310-K,  4
1/28/2310-K,  ARS
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/03/24  Petco Health & Wellness Co., Inc. 10-K        2/03/24   90:19M                                    Donnelley … Solutions/FA
Top
Filing Submission 0001193125-24-066384   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 8:53:41.1am ET